Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Finasteride wins 1 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
Shared outcomes (1)
Outcomes where both Finasteride and HCG (Human Chorionic Gonadotropin) have evidence — compare verdict strength side-by-side.
1 mg once daily for male pattern hair loss (Propecia); 5 mg once daily for benign prostatic hyperplasia (Proscar). A prescription drug — use under a clinician.
any
Oral tablet (1 mg for hair, 5 mg for BPH)
Prescription-only and indication-dependent. For fertility preservation / intratesticular-testosterone maintenance on TRT, small studies used ~125-500 IU subcutaneously every other day. For spermatogenesis induction in hypogonadotropic hypogonadism, typically ~1,000-2,500 IU two to three times weekly (often combined with FSH), titrated to response. For female ovulation/oocyte-maturation trigger, a single dose (~5,000-10,000 IU urinary or 250 µg recombinant). No dietary-supplement dose exists.
any
Prescription hCG — recombinant (choriogonadotropin alfa) or urinary-derived, by injection
3-12 months to visible effect
Months to years
Throughout use; sometimes persistent
Throughout use
Weeks
Months
Months
Within ~36 hours
Finasteride in the treatment of men with androgenetic alopecia.
Journal of the American Academy of Dermatology (1998) · Rct · n=1553
Pivotal double-blind randomized, placebo-controlled trials of finasteride 1 mg/day for male pattern hair loss
Long-term (5-year) multinational experience with finasteride 1 mg in the treatment of men with androgenetic alopecia.
European journal of dermatology : EJD (2002) · Rct · n=1553
Five-year placebo-controlled extension of the pivotal Phase III hair-loss trials
The impact of monotherapies for male androgenetic alopecia: A network meta-analysis study.
Journal of cosmetic dermatology (2024) · Meta analysis
Network meta-analysis of monotherapies for male androgenetic alopecia
Low-dose human chorionic gonadotropin maintains intratesticular testosterone in normal men with testosterone-induced gonadotropin suppression.
J Clin Endocrinol Metab (2005) · Rct · n=29
29 men with normal reproductive physiology randomized to weekly testosterone enanthate plus saline placebo or 125, 250, or 500 IU hCG every other day for 3 weeks
Concomitant intramuscular human chorionic gonadotropin preserves spermatogenesis in men undergoing testosterone replacement therapy.
J Urol (2013) · Observational · n=26
Retrospective cohort of 26 hypogonadal men on testosterone replacement plus 500 IU intramuscular hCG every other day, mean follow-up 6.2 months
A combined analysis of data to identify predictive factors for spermatogenesis in men with hypogonadotropic hypogonadism treated with recombinant human follicle-stimulating hormone and human chorionic gonadotropin.
Fertil Steril (2009) · Observational · n=100
Combined analysis of four Phase III open-label studies in 100 men with complete idiopathic or acquired hypogonadotropic hypogonadism, pretreated with hCG for 3-6 months then hCG plus recombinant FSH
Finasteride has a higher evidence score (5.5/10 vs 5.5/10) and wins in 1 of 3 categories.
No known interactions between Finasteride and HCG (Human Chorionic Gonadotropin) have been documented in our database. However, always consult a healthcare provider before combining supplements.